Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | ME2 | P23368 | 2/20 | 0.41 |
| ▸ | ME1 | P48163 | 2/20 | 0.41 |
| ▸ | ME3 | Q16798 | 2/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754764 | 0.83 | OPRM1 (0.68) | OPRM1KCNH2OPRD1OPRK1NR3C2 | |
| SCHEMBL5753248 | 0.81 | OPRM1 (0.74) | OPRM1KCNH2OPRD1OPRK1ALDH1A1 | |
| SCHEMBL5753714 | 0.79 | OPRM1 (0.53) | OPRM1KCNH2OPRD1OPRK1ME2 | |
| SCHEMBL5758139 | 0.77 | OPRM1 (0.55) | OPRM1KCNH2OPRD1OPRK1ALDH1A1 | |
| SCHEMBL5755086 | 0.77 | OPRM1 (0.55) | OPRM1KCNH2OPRD1OPRK1ALDH1A1 | |
| SCHEMBL5755630 | 0.76 | OPRM1 (0.59) | OPRM1KCNH2OPRD1OPRK1ALDH1A1 | |
| SCHEMBL5757445 | 0.76 | OPRM1 (0.59) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL5752273 | 0.76 | OPRM1 (0.67) | OPRM1KCNH2OPRD1OPRK1NR3C2 | |
| SCHEMBL5757484 | 0.76 | OPRM1 (0.54) | OPRM1KCNH2OPRD1OPRK1 | |
| SCHEMBL5753623 | 0.76 | OPRM1 (0.53) | OPRM1KCNH2OPRD1OPRK1ME2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140828-B1 | 3-AZABICYCLO¬3.1.0|HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| US-7049444-B2 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. (US) | 2006-05-23 | — | — | US | disclosed |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER, INC. (US) | 2003-01-16 | — | — | US | disclosed |
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6313312-B1 | OPIATE RECEPTOR BINDERS; ALLERGIC DERMATITIS, PRURITUS; IRRITABLE BOWEL SYNDROME, GASTROINTESTINAL AND SKIN DISORDERS; VETERINARY MEDICINE; ANTI-ITCHING | PFIZER INC | 2001-11-06 | — | — | US | disclosed |
| EP-1140828-A1 | 3-AZABICYCLO[3.1.0]HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039089-A1 | 3-AZABICYCLO[3.1.0.] HEXANE DERIVATIVES AS OPIATE RECEPTORS LIGANDS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072616-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885KCNH2 3004/4885OPRD1 3/4885 |
| US-20030013875-A1 | 3-azabicyclo[3.1.0]hexane derivatives useful in therapy | OPRM1, OPRK1, OPRD1 | OPRM1 1/4885KCNH2 3004/4885OPRD1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.